A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

APPROVED_FOR_MARKETING

Conditions studied: Basal Cell Carcinoma

In brief

This is an open-label, non-comparative, multicenter, expanded access study of Vismodegib (GDC-0449) in patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC (mBCC) who are otherwise without satisfactory treatment options.

Key facts

Study ID

NCT01160250

Run by

Genentech, Inc.

Starts

2010-07-01

Expected to finish

2012-04-01

Last updated by the study team

2015-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• For patients with mBCC, histologic confirmation of distant BCC metastasis
• For patients with locally advanced BCC, at least one histologically confirmed lesion 10 mm or more in diameter and written confirmation from a surgical specialist that the tumor is considered inoperable or that surgery is contraindicated
• For patients with locally advanced BCC, radiotherapy must have been previously administered for locally advanced BCC, unless radiotherapy is contraindicated or inappropriate. For patients whose locally advanced BCC has been irradiated, disease must have progressed after radiation.
• Patients with Gorlin syndrome may enroll in this study but must meet the criteria for locally advanced or metastatic disease listed above
• Patients with measurable and/or non-measurable disease (as defined by RECIST) are allowed
• Adequate organ function
• For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 12 months after discontinuation of Vismodegib (GDC-0449)
• For men with female partners of childbearing potential, agreement to use a latex condom, and to advise their female partner to use an additional method of contraception during the study and for 3 months after discontinuation of Vismodegib (GDC-0449)

You may not qualify if…

• Pregnancy or lactation
• Life expectancy < 12 weeks
• Concurrent non-protocol-specified anti-tumor therapy
• Completion of most recent anti-tumor therapy at least 21 days prior to initiation of treatment
• Uncontrolled medical illnesses such as infection requiring treatment with intravenous antibiotics
• History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk from treatment complications
• Unwillingness to practice effective birth control

Where it is running

• Study site — Scottsdale, Arizona, United States
• Study site — Scottsdale, Arizona, United States
• Study site — Los Angeles, California, United States
• Study site — Stanford, California, United States
• Study site — Ormond Beach, Florida, United States
• Study site — Detroit, Michigan, United States
• Study site — New York, New York, United States
• Study site — Columbus, Ohio, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Nashville, Tennessee, United States
• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.